"TBSF" Human Immunoglobulin for Intravenous Use

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

normal immunoglobulin, Quantity: 60 g/L

Pieejams no:

CSL Behring Australia Pty Ltd

SNN (starptautisko nepatentēto nosaukumu):

normal immunoglobulin

Zāļu forma:

Injection, solution

Kompozīcija:

Excipient Ingredients: maltose

Ievadīšanas:

Intravenous

Vienības iepakojumā:

50mL, 200mL

Klase:

Medicine Listed (Export Only)

Receptes veids:

(S1) This Schedule is intentionally blank

Ārstēšanas norādes:

TBSF Human Immunoglobulin for Intravenous Use is indicated for replacement IgG therapy in: * primary immunodeficiency (PID) * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. TBSF Human Immunoglobulin for Intravenous Use is indicated for immunomodulatory therapy in: * Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count * allogeneic bone marrow transplantation * Kawasaki disease * Guillain-Barre Syndrome (GBS).

Produktu pārskats:

Visual Identification: Clear, colourless solution; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Autorizācija statuss:

Listed (Export Only)

Autorizācija datums:

2006-03-01